Special Report: Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220. The new test would be used in the ongoing RAC-010 cardioprotection and anticancer synergy (CPACS) trial to provide a more precise understanding of RC220’s ability to protect the molecular pathways responsible for anthracycline-induced cardiotoxicity.

Read the full article: https://stockhead.com.au/health/racura-scientists-develop-cardioprotection-blood-test-to-support-key-trial/